Population pharmacokinetics of mobocertinib in healthy volunteers and patients with non–small cell lung cancer
N Gupta, PB Pierrillas, MJ Hanley… - CPT …, 2022 - Wiley Online Library
… Neeraj Gupta is employed by Takeda; Philippe B. Pierrillas is employed by Certara and is a
consultant for Takeda; Michael J. Hanley is employed by Takeda; Steven Zhang is employed …
consultant for Takeda; Michael J. Hanley is employed by Takeda; Steven Zhang is employed …
[HTML][HTML] Model-based adaptive optimal design (MBAOD) improves combination dose finding designs: an example in oncology
Abstract Design of phase 1 combination therapy trials is complex compared to single therapy
trials. In this work, model-based adaptive optimal design (MBAOD) was exemplified and …
trials. In this work, model-based adaptive optimal design (MBAOD) was exemplified and …
Comparison of the static in vivo approach to a physiologically based pharmacokinetic approach for metabolic drug–drug interactions prediction
M Tod, PB Pierrillas, L Bourguignon… - International journal of …, 2016 - Future Science
Background: The in vivo mechanistic static model (IMSM) and the physiologically based
pharmacokinetic (PBPK) model are two approaches used to predict the magnitude of drug–drug …
pharmacokinetic (PBPK) model are two approaches used to predict the magnitude of drug–drug …
Prediction of human nonlinear pharmacokinetics of a new Bcl-2 inhibitor using PBPK modeling and interspecies extrapolation strategy
PB Pierrillas, E Henin, K Ball, J Ogier, M Amiel… - Drug Metabolism and …, 2019 - ASPET
S 55746 ((S)-N-(4-hydroxyphenyl)-3-(6-(3-(morpholinomethyl)-1,2,3,4-tetrahydroisoquinoline-2-carbonyl)benzo[d][1,3]dioxol-5-yl)-N-phenyl-5,6,7,8-tetrahydroindolizine-1-carboxamide) …
[HTML][HTML] Improvement of parameter estimations in tumor growth inhibition models on xenografted animals: a novel method to handle the interval censoring caused by …
The purpose of this study was to explore the interval censoring induced by caliper measurements
on smaller tumors during tumor growth experiments in preclinical studies and to show …
on smaller tumors during tumor growth experiments in preclinical studies and to show …
Improvement of parameter estimations in tumor growth inhibition models on xenografted animals: handling sacrifice censoring and error caused by experimental …
The purpose of this study was to explore the impact of censoring due to animal sacrifice on
parameter estimates and tumor volume calculated from two diameters in larger tumors during …
parameter estimates and tumor volume calculated from two diameters in larger tumors during …
Tumor growth inhibition modelling based on receptor occupancy and biomarker activity of a new Bcl-2 inhibitor in mice
PB Pierrillas, E Henin, J Ogier, L Kraus-Berthier… - … of Pharmacology and …, 2018 - ASPET
The Bcl-2 inhibitor S 55746 ((S)-N-(4-hydroxyphenyl)-3-(6-(3-(morpholinomethyl)-1,2,3,4-tetrahydroisoquinoline-2-carbonyl)benzo[d][1,3]dioxol-5-yl)-N-phenyl-5,6,7,8-…
Translational approach from preclinical to clinical: comparison of dose finding methods of a new Bcl2 inhibitor using PK-PD modeling and interspecies extrapolation
PB Pierrillas, E Henin, J Ogier, M Amiel… - Investigational New …, 2020 - Springer
The attrition rate of anticancer drugs during the clinical development remains very high.
Interspecies extrapolation of anticancer drug pharmacodynamics (PD) could help to bridge the …
Interspecies extrapolation of anticancer drug pharmacodynamics (PD) could help to bridge the …
[PDF][PDF] Evaluation of DDI-predictor for prediction of the impact of CYP polymorphism on drug exposure.
M Tod, PB Pierrillas, L Bourguigon, S Goutelle - ddi-predictor.org
• Quantitative prediction of the impact of cytochrome (CYP) polymorphism on drug exposure
is useful to identify the pharmacogenetic studies to be performed during clinical drug …
is useful to identify the pharmacogenetic studies to be performed during clinical drug …
Population PK and semimechanistic PK/PD modeling and simulation of relugolix effects on testosterone suppression in men with prostate cancer
TY Lee, PB Pierrillas, YW Lin… - Clinical …, 2023 - Wiley Online Library
Relugolix, the first orally active, nonpeptide gonadotropin‐releasing hormone receptor
antagonist, is approved in the United States and the European Union for the treatment of adult …
antagonist, is approved in the United States and the European Union for the treatment of adult …